CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

The Tigers will have a week to lick their wounds from this loss before they are back on the road for their sixth SEC matchup of the season. They will face another ranked foe in No. 4 Alabama at 7: ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Against a fellow winless team in the SEC, Arkansas (11-6, 0-4) let leads of 12 and eight points slip away in a 78-74 loss at LSU (12-5, 1-3). After three losses to three ranked teams to kick off the ...

So far, Retatrutide, developed by Eli Lilly, has achieved an efficacy rate of 24%, ahead of CagriSema. Previously, the biggest challenge facing Novo Nordisk and Eli Lilly — beyond their rivalry — was ...